Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 8;11(11):1573.
doi: 10.3390/antibiotics11111573.

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa

Elisa Molinelli  1 , Claudia Sapigni  1 , Giovanni Marco D'Agostino  1 , Valerio Brisigotti  1 , Giulio Rizzetto  1 , Ivan Bobyr  1 , Oscar Cirioni  1 , Andrea Giacometti  2 , Lucia Brescini  2 , Sara Mazzanti  2 , Annamaria Offidani  1 , Oriana Simonetti  1
Affiliations

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa

Elisa Molinelli et al. Antibiotics (Basel). .

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and fistulas, localized to the areas of the folds where apocrine glands are present: the armpits, groin, inframammary region, and genital or perineal region. The management is still challenging, and it includes mainly systemic antibiotics, immunosuppressors, and biologic agents. Antibiotics are frequently used in the management of HS for their anti-inflammatory, immunomodulatory, and antimicrobial properties, but no data have been reported regarding the use of dalbavancin in HS. The aim of our practice was to evaluate efficacy, flare, and disease-free survival after dalbavancin therapy in a selected population with HS. We report the experience of the Ancona Dermatology Clinic in treating HS flare-ups with dalbavancin and its rationale for use. Our observation shows that the use of dalbavancin is an effective and well-tolerated treatment for the management of Hurley stage II-III HS; currently, dalbavancin should be considered as a supportive therapy for selected patients.

Keywords: antibiotics; biologic agents; dalbavancin; hidradenitis suppurativa; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Offidani A., Molinelli E., Sechi A., Brisigotti V., Campanati A., Raone B., Neri I., Patrizi A. Hidradenitis suppurativa in a prepubertal case series: A call for specific guidelines. J. Eur. Acad. Dermatol. Venereol. 2019;33:28–31. doi: 10.1111/jdv.15827. - DOI - PubMed
    1. Zouboulis C.C., Benhadou F., Byrd A.S., Chandran N.S., Giamarellos-Bourboulis E.J., Fabbrocini G., Frew J.W., Fujita H., González-López M.A., Guillem P., et al. What causes hidradenitis suppurativa ?—15 years after. Exp. Dermatol. 2020;29:1154–1170. doi: 10.1111/exd.14214. - DOI - PubMed
    1. Bettoli V., Manfredini M., Massoli L., Carillo C., Barozzi A., Amendolagine G., Ruina G., Musmeci D., Libanore M., Curtolo A., et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J. Eur. Acad. Dermatol. Venereol. 2019;33:930–936. doi: 10.1111/jdv.15332. - DOI - PubMed
    1. Alikhan A., Sayed C., Alavi A., Alhusayen R., Brassard A., Burkhart C., Crowell K., Eisen D.B., Gottlieb A.B., Hamzavi I., et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J. Am. Acad. Dermatol. 2019;81:91–101. doi: 10.1016/j.jaad.2019.02.068. - DOI - PMC - PubMed
    1. Lacarrubba F., Dini V., Napolitano M., Venturini M., Caposeina Caro D.R., Molinelli E., Passoni E., Monfrecola G. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: The Italian Ultrasound Working Group experience. J. Eur. Acad. Dermatol. Venereol. 2019;33:10–14. doi: 10.1111/jdv.15847. - DOI - PubMed

LinkOut - more resources